

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 8,071,092 B1
APPLICATION NO. : 09/589288
DATED : December 6, 2011
INVENTOR(S) : Yu et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

TITLE PAGE

Left column, under (75) Inventors, "Gatihersburg" should read -- Gaithersburg --
Left column, Related U.S. Application Data, under (63), line 2, "and" should read
-- which is --
Left column, Related U.S. Application Data, under (63), line 7, "and" should read
-- which is --

TITLE PAGE 14 (CONTINUATION OF OTHER PUBLICATIONS)

Right column, line 26, "Vvaterston" should read -- Waterston --
Right column, line 30, "Yoshi Moto" should read -- Yoshimoto --

TITLE PAGE 15 (CONTINUATION OF OTHER PUBLICATIONS)

Right column, after the last cited publication, please insert the following publications:
-- ZymoGenetics' Observations in Reply (158 pages) to Oppositions of EP Patent No. 1141274 lodged by Corixa Corporation, Human Genome Sciences, Inc., Genentech, Inc., and Biogen Idec, Inc. The Observations in Reply was filed in the European Patent Office on June 7, 2005.
Stohl, W., "A therapeutic role for BLyS antagonists," *Lupus*, 13:317-322 (2004).
Novak et al., "Expression of BlyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome," *Blood*, 104(8):2247-2253 (2004).
European Search Report, European Application No. EP 05 01 2261, mailed August 8, 2005. --

IN THE SPECIFICATION

Column 1, delete lines 5-29, and insert -- This application is a continuation of U.S. Application No. 09/507,968, filed February 22, 2000 (now U.S. Patent No. 6,812,327 issued November 2, 2004) which claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Application Nos. 60/122,388 filed March 2, 1999, 60/124,097 filed March 12, 1999, 60/126,599 filed March 26, 1999, 60/127,598 filed April 2, 1999, 60/130,412 filed April 16, 1999, 60/130,696 filed April 23, 1999, 60/131,278 filed April

Signed and Sealed this
Nineteenth Day of March, 2013



Teresa Stanek Rea
Acting Director of the United States Patent and Trademark Office

U.S. Pat. No. 8,071,092 B1

27, 1999, 60/131,673 filed April 29, 1999, 60/136,784 filed May 28, 1999, 60/142,659 filed July 6, 1999, 60/145,824 filed July 27, 1999, 60/167,239 filed November 24, 1999, 60/168,624 filed December 3, 1999, 60/171,108 filed December 16, 1999, 60/171,626 filed December 23, 1999, and 60/176,015 filed January 14, 2000; U.S. Application No. 09/507,968, filed February 22, 2000 (now U.S. Patent No. 6,812,327 issued November 2, 2004) is also a continuation-in-part of U.S. Application No. 09/255,794, filed February 23, 1999 (now U.S. Patent No. 6,716,576 issued April 6, 2004) which is a continuation-in-part of U.S. Application No. 09/005,874, filed January 12, 1998 (now U.S. Patent No. 6,689,579 issued February 10, 2004) which is a continuation-in-part of International Patent Application No. PCT/US96/17957, filed October 25, 1996, and claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/036,100, filed January 14, 1997. Each --

Column 12, line 16, “granulamatous” should read -- granulomatous --

Column 32, line 4, “e.g.” should read -- e.g., --

Column 128, line 56, “pleuripotent” should read -- pluripotent --

Column 148, line 45, “e.g.” should read -- e.g., --

Column 151, line 58, “e.g.” should read -- e.g., --

Column 162, line 20, “preferable” should read -- preferably --

Column 168, line 1, “e.g.” should read -- e.g., --

Column 171, line 50, “Sjogren” should read -- Sjogren’s --

Column 186, line 23, “i.e.” should read -- i.e., --

Column 190, line 5, “granulamatous” should read -- granulomatous --

Column 191, line 32, “inflammatory” should read -- inflammatory --

Column 197, lines 10-11, “discreet” should read -- discrete --

Column 197, line 12, “discreet” should read -- discrete --

Column 202, line 19, “e.g.” should read -- e.g., --

Column 205, line 47, “compostions” should read -- compositions --

Column 210, line 34, “e.g.” should read -- e.g., --

Column 211, line 2, “e.g.” should read -- e.g., --

Column 213, line 30, “protein” should read -- proteins --

Column 218, line 11, “TCA TGA” should read -- TCA TGA --

Column 218, line 20, “AAG CTT” should read -- AAG CTT --

Column 222, line 22, “KD” should read -- kDa --

Column 225, line 2, “kd” should read -- kDa --

Column 244, line 28, after “Jan. 12, 1998” please insert -- (now U.S. Patent 6,689,579, issued February 10, 2004) --

IN THE CLAIMS

Column 285, line 10, in claim 67, “Neutrokin-a” should read -- Neutrokin- α --

Column 286, line 4, in claim 83, “Neutrokin-a” should read -- Neutrokin- α --